Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.

Kawachi H, Yamada T, Tamiya M, Negi Y, Kijima T, Goto Y, Nakao A, Shiotsu S, Tanimura K, Takeda T, Okada A, Harada T, Date K, Chihara Y, Hasegawa I, Tamiya N, Katayama Y, Nishioka N, Morimoto K, Iwasaku M, Tokuda S, Shimose T, Takayama K

Open source

DOI: 10.1080/2162402x.2024.2442116
Published: 2025 Dec
Container: Oncoimmunology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/2162402x.2024.2442116,
  title = {Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50\% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.},
  author = {Kawachi H and Yamada T and Tamiya M and Negi Y and Kijima T and Goto Y and Nakao A and Shiotsu S and Tanimura K and Takeda T and Okada A and Harada T and Date K and Chihara Y and Hasegawa I and Tamiya N and Katayama Y and Nishioka N and Morimoto K and Iwasaku M and Tokuda S and Shimose T and Takayama K},
  year = {2025},
  journal = {Oncoimmunology},
  doi = {10.1080/2162402x.2024.2442116},
  url = {https://doi.org/10.1080/2162402x.2024.2442116}
}

RIS

TY  - JOUR
TI  - Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.
AU  - Kawachi H
AU  - Yamada T
AU  - Tamiya M
AU  - Negi Y
AU  - Kijima T
AU  - Goto Y
AU  - Nakao A
AU  - Shiotsu S
AU  - Tanimura K
AU  - Takeda T
AU  - Okada A
AU  - Harada T
AU  - Date K
AU  - Chihara Y
AU  - Hasegawa I
AU  - Tamiya N
AU  - Katayama Y
AU  - Nishioka N
AU  - Morimoto K
AU  - Iwasaku M
AU  - Tokuda S
AU  - Shimose T
AU  - Takayama K
PY  - 2025
JO  - Oncoimmunology
DO  - 10.1080/2162402x.2024.2442116
UR  - https://doi.org/10.1080/2162402x.2024.2442116
ER  -

APA

H, K., T, Y., M, T., Y, N., T, K., Y, G., A, N., S, S., K, T., T, T., A, O., T, H., K, D., Y, C., I, H., N, T., Y, K., N, N., K, M., M, I., S, T., T, S., & K, T. (2025). Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy.. Oncoimmunology. https://doi.org/10.1080/2162402x.2024.2442116

Source records

pubmed · retrieved 2026-09-27T00:46:30.692Z
europe-pmc · retrieved 2026-09-27T00:46:30.707Z
doaj · retrieved 2026-09-27T00:46:30.701Z